Search results
11 gru 2020 · COMIRNATY ® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech. It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older; It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:
- View PDF
The Pfizer-BioNTech COVID-19 Vaccine has received EUA from...
- Vaccines Manufacturing B-roll Video
This information—including product information—is intended...
- View PDF
22 sie 2024 · Individuals 12 years of age and older are eligible to receive a single dose of the updated, approved Comirnaty or the updated, approved Spikevax; if previously vaccinated, the dose is...
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [33] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing.
28 sie 2024 · Pfizer-BioNTech COVID-19 Vaccine is indicated for individuals 5 through 11 years of age (via a 10mcg / 0.3mL single-dose vial presentation) and for individuals 6 months through 4 years of age (via a 3mcg / 0.3mL multi-dose vial (3 doses per vial) presentation).
25 cze 2022 · COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine approved for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. COMIRNATY® is administered as a 2-dose primary series.
1 wrz 2022 · EMA’s human medicines committee (CHMP) has recommended authorising two vaccines adapted to provide broader protection against COVID-19. Comirnaty Original/Omicron BA.1 and Spikevax bivalent Original/Omicron BA.1 are for use in people aged 12 years and above who have received at least primary vaccination against COVID-19.
22 sie 2024 · COMIRNATY is an FDA-approved vaccine for prevention of COVID-19 in individuals 12 years of age and older that is authorized under EUA to complete the dosing schedule for immunocompromised...
